Citigroup’s Vaxart VXRT Stock Holding History

Citigroup’s Portfolio VXRT Stock Details VXRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-50,000	Closed	-$375K	–	6337
2021 Q2	$375K	Buy	+50,000	New	+$349K	﹤0.01%	3886
2021 Q1	–	Sell	-26,700	Closed	-$152K	–	7479
2020 Q4	$152K	Buy	+26,700	New	+$170K	﹤0.01%	5200

Other funds holding VXRT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citigroup's VXRT Position: Q1 2025 in Review

Citigroup sold out of Vaxart (VXRT) in Q1 2025, closing a stake of 1,464 shares — an estimated $969 sold.

Citigroup first reported a position in VXRT in Q2 2013 and held it in 22 quarters. The position peaked at $4.14M in Q4 2021. 92 funds tracked by Wall St. Rank hold VXRT as of Q1 2025.

Citigroup reported no remaining Vaxart position as of Q1 2025 after selling out during the quarter.
Citigroup sold 1,464 Vaxart shares in Q1 2025, an estimated $969.
Citigroup first reported a position in Vaxart in Q2 2013 and held it in 22 quarters.
Citigroup's Vaxart position peaked at $4.14M in Q4 2021.
92 funds tracked by Wall St. Rank held Vaxart as of Q1 2025.

Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.